Vyepti: Uses, Dosage & Side Effects
A CGRP-targeting monoclonal antibody administered by intravenous infusion for the preventive treatment of migraine in adults with 4 or more migraine days per month
Vyepti (eptinezumab) is a prescription monoclonal antibody used for the preventive treatment of migraine in adults. It works by selectively binding to and neutralizing calcitonin gene-related peptide (CGRP), a neuropeptide centrally involved in migraine pathophysiology. Vyepti is unique among CGRP-targeting therapies as the only one administered by intravenous infusion, given over approximately 30 minutes every 12 weeks in a clinical setting. This IV route provides immediate peak blood levels and rapid onset of preventive effect, with many patients experiencing benefit starting the day after the first infusion. Available in 100 mg and 300 mg doses, Vyepti has demonstrated significant reductions in monthly migraine days in large-scale clinical trials involving both episodic and chronic migraine patients.
Quick Facts: Vyepti
Key Takeaways
- Vyepti (eptinezumab) is the only CGRP-targeting monoclonal antibody given by intravenous infusion, providing immediate peak blood levels and rapid onset of migraine prevention starting as early as the day after the first dose.
- Administered once every 12 weeks (quarterly) by a healthcare professional in approximately 30 minutes, eliminating the need for self-injection at home.
- Clinical trials (PROMISE-1 and PROMISE-2) demonstrated significant reductions in monthly migraine days in both episodic and chronic migraine, with a 50% or greater reduction achieved by a substantial proportion of patients.
- Generally well tolerated with the most common side effects being nasal congestion, sore throat, and fatigue; allergic reactions during or after infusion can occur but are usually mild.
- Available in 100 mg and 300 mg doses, with the choice of dose determined by the treating physician based on the patient’s individual migraine burden and treatment response.
What Is Vyepti and What Is It Used For?
Vyepti contains the active substance eptinezumab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody produced using recombinant DNA technology. As a monoclonal antibody, Vyepti is a highly specialized protein engineered to recognize and bind to one specific molecular target in the body. In the case of Vyepti, that target is calcitonin gene-related peptide (CGRP), a 37-amino acid neuropeptide that has been identified as a central mediator in the pathophysiology of migraine.
CGRP is one of the most potent vasodilators known and is abundantly expressed in the trigeminal sensory neurons, dorsal root ganglia, and perivascular nerve fibers surrounding cerebral and meningeal blood vessels. During a migraine attack, CGRP is released in large quantities from trigeminal sensory nerve endings. This release initiates a cascade of pathophysiological events including vasodilation of intracranial blood vessels, neurogenic inflammation of the meninges, sensitization of pain-processing neurons in the trigeminal nucleus caudalis, and transmission of nociceptive signals to higher brain centers including the thalamus and cortex. Elevated CGRP concentrations have been consistently measured in the jugular venous blood of patients during acute migraine attacks, and intravenous infusion of CGRP has been shown to provoke migraine-like headaches in susceptible individuals, providing strong evidence for its causal role.
Eptinezumab binds with high affinity to both the alpha and beta isoforms of CGRP, preventing the peptide from activating its receptor (the CGRP receptor, composed of the calcitonin receptor-like receptor and receptor activity-modifying protein 1). By neutralizing circulating CGRP before it can initiate the migraine cascade, eptinezumab effectively reduces the frequency of migraine attacks, decreases headache severity, and lowers the need for acute rescue medications such as triptans and analgesics. As a large molecule, eptinezumab does not cross the blood-brain barrier in significant amounts and is believed to exert its preventive effects primarily in the peripheral trigeminovascular system.
What distinguishes Vyepti from other CGRP-targeting monoclonal antibodies (such as erenumab, fremanezumab, and galcanezumab) is its route of administration. While the other agents in this class are given as subcutaneous injections, Vyepti is administered as an intravenous (IV) infusion over approximately 30 minutes. This IV delivery provides immediate and complete bioavailability, achieving maximum serum concentrations at the end of the infusion rather than requiring days to reach peak levels. This pharmacokinetic advantage translates into a potentially faster onset of preventive effect, with patients in clinical trials experiencing benefit starting as early as the day after the first infusion.
Vyepti is indicated for the preventive treatment of migraine in adults who experience at least 4 migraine days per month. This includes patients with both episodic migraine (fewer than 15 headache days per month) and chronic migraine (15 or more headache days per month, of which at least 8 are migraine days). The efficacy and safety of Vyepti were established in two pivotal phase III clinical trials:
- PROMISE-1 (Prevention of Migraine via Intravenous ALD403 Safety and Efficacy – 1): This randomized, double-blind, placebo-controlled trial enrolled 888 adults with episodic migraine. Patients received IV infusions of eptinezumab 100 mg, 300 mg, or placebo every 12 weeks for 48 weeks. Both dose groups showed statistically significant reductions in monthly migraine days compared with placebo over the primary 12-week endpoint. The 100 mg group experienced a mean reduction of 3.9 migraine days per month versus 3.2 for placebo, and the 300 mg group experienced a mean reduction of 4.3 days versus 3.2 for placebo. Notably, the onset of benefit was rapid: within the first month, 49.8% of patients in the 100 mg group and 56.3% in the 300 mg group achieved a 50% or greater reduction in monthly migraine days.
- PROMISE-2 (Prevention of Migraine via Intravenous ALD403 Safety and Efficacy – 2): This trial enrolled 1,072 adults with chronic migraine. Patients received IV infusions of eptinezumab 100 mg, 300 mg, or placebo every 12 weeks for 24 weeks. Both doses demonstrated statistically significant reductions in monthly migraine days compared with placebo. The 100 mg group achieved a mean reduction of 7.7 migraine days per month versus 5.6 for placebo, and the 300 mg group achieved a reduction of 8.2 days versus 5.6 for placebo. A remarkable 57.6% of patients in the 300 mg group achieved a 50% or greater reduction in monthly migraine days at weeks 1–12.
Vyepti was first approved by the U.S. Food and Drug Administration (FDA) in February 2020 and subsequently by the European Medicines Agency (EMA) in January 2022. It is marketed globally by H. Lundbeck A/S. Vyepti represents an important treatment option for migraine patients who prefer the convenience of quarterly infusions in a clinical setting over monthly or quarterly self-injections, and for those who may benefit from the rapid onset of action associated with IV delivery.
Because Vyepti is given intravenously, it achieves 100% bioavailability immediately at the end of the infusion. This means there is no absorption phase as with subcutaneous injections, allowing eptinezumab to begin neutralizing CGRP right away. In clinical trials, patients reported fewer migraines as early as the day after their first infusion, making Vyepti a compelling choice for patients seeking rapid preventive relief.
What Should You Know Before Taking Vyepti?
Contraindications
The primary contraindication to Vyepti use is hypersensitivity (allergy) to eptinezumab or to any of the other ingredients in the formulation. The excipients in Vyepti include sorbitol (E420), L-histidine, L-histidine hydrochloride monohydrate, polysorbate 80, and water for injections. If you have a known allergy to any of these substances, you must not receive Vyepti.
Patients with hereditary fructose intolerance should not receive Vyepti. The formulation contains sorbitol, which is a source of fructose. In patients with this rare inherited condition, fructose cannot be broken down properly, which can lead to serious adverse effects including hypoglycemia, liver damage, and metabolic acidosis. If you have hereditary fructose intolerance, inform your doctor before receiving this medication.
Warnings and Precautions
Vyepti can cause serious allergic reactions that may develop rapidly during the infusion or shortly afterward. Seek immediate medical attention if you experience difficulty breathing, rapid or weak pulse, sudden drop in blood pressure causing dizziness or lightheadedness, swelling of lips or tongue, or severe itching or skin rash. Healthcare professionals will monitor you during and after the infusion as standard clinical practice.
Before starting Vyepti, discuss the following with your healthcare provider:
- Cardiovascular disease: Talk to your doctor if you have a condition affecting the heart and blood vessels. CGRP plays a role in cardiovascular protection, including vasodilation and blood pressure regulation. While current clinical trial data have not identified significant cardiovascular safety signals with eptinezumab, patients with established cardiovascular disease should be monitored and should discuss potential risks with their doctor. Patients with certain cardiovascular conditions were excluded from the pivotal clinical trials.
- History of allergic reactions: Vyepti can cause allergic reactions and infusion-related reactions that may develop rapidly during administration. Symptoms can include difficulty breathing, rapid or weak pulse, sudden drop in blood pressure, swelling of the lips or tongue, and severe itching or rash. Serious allergic reactions (anaphylaxis) have been reported in up to 1 in 100 patients. Your healthcare team will observe you during and after each infusion.
- Polysorbate 80 sensitivity: Vyepti contains 0.15 mg polysorbate 80 per mL. Polysorbate 80 can cause allergic reactions in some individuals. Inform your doctor if you have any known allergies to polysorbate-containing products.
Children and Adolescents
Vyepti is not recommended for use in children and adolescents under 18 years of age. The safety and efficacy of eptinezumab have not been established in this age group, and no clinical trial data are available to support pediatric use. Migraine in children and adolescents may require different treatment approaches, and healthcare providers should consider age-appropriate alternatives including lifestyle modifications, behavioral therapies, and medications with established pediatric safety profiles.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, or are planning to become pregnant, consult your doctor before receiving Vyepti. The effects of eptinezumab on human pregnancy are not known. As a monoclonal antibody (IgG1), eptinezumab is expected to cross the placental barrier, particularly during the second and third trimesters when active IgG transport mechanisms are most active. Animal reproductive studies are not always predictive of human response, and the potential risks to a developing fetus have not been fully characterized. As a precaution, Vyepti should preferably be avoided during pregnancy unless the treating physician determines that the potential benefit to the mother clearly outweighs any potential risk to the fetus.
It is not known whether eptinezumab passes into human breast milk. Human IgG antibodies are known to be present in breast milk, particularly during the early postnatal period. A risk to the breastfed infant cannot be excluded. If you are breastfeeding or planning to breastfeed, discuss with your doctor before receiving Vyepti. You and your doctor should weigh the benefits of breastfeeding for the infant against the benefits of Vyepti treatment for you to make an informed decision.
Driving and Operating Machinery
Vyepti has no or negligible effect on the ability to drive or operate machinery. Based on its pharmacological profile and the adverse effects observed in clinical trials, eptinezumab is not expected to impair your ability to perform tasks requiring concentration or coordination. However, as with any medication, if you experience any side effects that could affect your alertness or coordination, refrain from driving or operating machinery until you feel well again.
Important Information About Ingredients
Vyepti contains sorbitol (E420), which is a source of fructose. If you have hereditary fructose intolerance, a rare genetic condition, you must not receive this medication. Fructose cannot be properly metabolized in patients with this condition, potentially causing serious adverse effects. You must inform your doctor before receiving Vyepti if you have been diagnosed with hereditary fructose intolerance.
Vyepti also contains polysorbate 80 (0.15 mg per mL). Polysorbate 80 is an emulsifier commonly used in pharmaceutical formulations and can occasionally cause allergic reactions in sensitive individuals. If you have any known allergies to polysorbate-containing products, inform your healthcare provider before treatment.
How Does Vyepti Interact with Other Drugs?
One of the practical advantages of Vyepti is its favorable drug interaction profile. Because eptinezumab is a monoclonal antibody (a large protein molecule), it is not metabolized by the cytochrome P450 (CYP) enzyme system in the liver, which is responsible for metabolizing the majority of small-molecule drugs. This means that eptinezumab does not compete with other medications for CYP-mediated metabolism and is not expected to alter the blood levels or effectiveness of other drugs through enzyme inhibition or induction.
No formal drug interaction studies have been conducted with Vyepti because the pharmacological characteristics of monoclonal antibodies make clinically significant pharmacokinetic interactions highly unlikely. Eptinezumab is degraded through general protein catabolic pathways (broken down into small peptides and amino acids) rather than through hepatic metabolism, further minimizing the risk of drug-drug interactions.
In clinical trials, patients receiving Vyepti were permitted to use concomitant acute and preventive migraine medications, and no signal of adverse interactions was detected. Vyepti can generally be used alongside the following medication classes commonly used in migraine management:
| Medication Class | Examples | Interaction Level | Notes |
|---|---|---|---|
| Triptans | Sumatriptan, Rizatriptan, Zolmitriptan | No interaction | Safe to use for acute migraine attacks during Vyepti treatment |
| NSAIDs | Ibuprofen, Naproxen, Aspirin | No interaction | Can be used as acute rescue medication |
| Beta-Blockers | Propranolol, Metoprolol, Atenolol | No interaction | May be used as add-on preventive therapy |
| Anticonvulsants | Topiramate, Valproate | No interaction | May be used as add-on preventive therapy |
| Antidepressants | Amitriptyline, Venlafaxine | No interaction | No pharmacokinetic interaction expected |
| Oral Contraceptives | Combined or progestogen-only pills | No interaction | Vyepti does not affect hormonal contraceptive efficacy |
Although no clinically significant interactions have been identified, you should always inform your healthcare provider about all medications you are currently taking, including prescription drugs, over-the-counter medicines, vitamins, and herbal supplements. This allows your doctor to monitor your overall treatment plan and ensure the best possible outcomes.
There is limited clinical experience with using Vyepti in combination with other CGRP-targeting treatments (such as erenumab, fremanezumab, galcanezumab, or gepants like rimegepant and ubrogepant). While no formal contraindication exists, combining multiple CGRP pathway inhibitors is generally not recommended as the additive benefit has not been established, and it could theoretically increase the risk of CGRP-related side effects. Discuss with your doctor if you are considering switching between CGRP-targeting therapies.
What Is the Correct Dosage of Vyepti?
Vyepti is administered exclusively as an intravenous (IV) infusion by trained healthcare professionals. Unlike other CGRP inhibitors that can be self-injected at home, Vyepti must be given in a healthcare setting such as a hospital outpatient clinic, infusion center, or specialized neurology practice. The concentrate for solution for infusion must be diluted before administration using a 100 mL bag of 0.9% sodium chloride solution.
Adults
Standard Dose
100 mg administered as an IV infusion over approximately 30 minutes, once every 12 weeks (quarterly).
Higher Dose Option
300 mg administered as an IV infusion over approximately 30 minutes, once every 12 weeks (quarterly). Your doctor may recommend this higher dose if they determine you may benefit from greater CGRP neutralization based on your migraine burden and treatment history.
The choice between the 100 mg and 300 mg dose is made by the treating physician based on several clinical factors, including the frequency and severity of the patient’s migraine attacks, previous treatment responses, and whether the patient has episodic or chronic migraine. In the PROMISE-2 trial in chronic migraine patients, the 300 mg dose showed numerically greater reductions in monthly migraine days compared with the 100 mg dose, although both doses were statistically superior to placebo.
| Patient Group | Dose | Route | Frequency | Notes |
|---|---|---|---|---|
| Adults (episodic migraine) | 100 mg | IV infusion (~30 min) | Every 12 weeks | Standard recommended starting dose |
| Adults (chronic migraine) | 100 mg or 300 mg | IV infusion (~30 min) | Every 12 weeks | 300 mg may offer greater benefit in chronic migraine |
| Children & Adolescents (<18 years) | Not recommended | N/A | N/A | Safety and efficacy not established |
| Elderly (≥65 years) | 100 mg or 300 mg | IV infusion (~30 min) | Every 12 weeks | No dose adjustment required; limited data in patients ≥65 |
| Renal / hepatic impairment | 100 mg or 300 mg | IV infusion (~30 min) | Every 12 weeks | No dose adjustment required (not renally/hepatically cleared) |
Administration Procedure
Vyepti must be prepared (reconstituted and diluted) by a healthcare professional using aseptic technique before it is administered. The concentrate from the single-use vial is withdrawn and injected into a 100 mL infusion bag containing 0.9% sodium chloride for injection. No other volumes or intravenous diluents may be used. The diluted solution should be gently inverted to mix completely and must not be shaken. The infusion should be completed within 8 hours of preparation.
During the infusion, healthcare staff will use an IV infusion set with an in-line or add-on 0.2 or 0.22 micrometer filter. After the infusion is complete, the line is flushed with 20 mL of 0.9% sodium chloride solution. Vyepti must not be administered as a bolus injection, and no other medications should be co-administered through the same infusion set.
Missed Dose
If you miss a scheduled Vyepti infusion appointment, contact your healthcare provider as soon as possible to reschedule. Your doctor will determine the appropriate timing for your next infusion. There is no need to double the dose to compensate for a missed appointment. Because Vyepti is given every 12 weeks, it is important to keep your scheduled appointments to maintain consistent migraine prevention.
Overdose
Because Vyepti is administered by healthcare professionals in a controlled clinical setting, the risk of accidental overdose is very low. In clinical studies, doses up to 1,000 mg were administered without dose-limiting toxicities. If an overdose is suspected, the patient should be monitored for any signs or symptoms of adverse reactions, and appropriate supportive treatment should be initiated as needed. There is no specific antidote for eptinezumab overdose.
What Are the Side Effects of Vyepti?
Like all medicines, Vyepti can cause side effects, although not everyone experiences them. Most side effects observed with Vyepti are mild to moderate in severity and are related to the infusion process itself. Your healthcare team will monitor you during and after each infusion for any signs of adverse reactions, as is standard clinical practice for intravenous medications.
The most clinically significant side effects to be aware of are allergic reactions and infusion-related reactions. These can develop rapidly during the infusion itself. If you experience any symptoms of an allergic reaction, tell your doctor or nurse immediately so they can intervene promptly. Symptoms to watch for include difficulty breathing, rapid or weak pulse, sudden drop in blood pressure causing dizziness or lightheadedness, swelling of the lips or tongue, and severe itching or skin rash.
Contact your doctor or nurse immediately if you notice any of the following during or after your Vyepti infusion: difficulty breathing, rapid or weak heartbeat, sudden feeling of dizziness or faintness, swelling of the lips, tongue, or face, severe itching or widespread rash. These may be signs of a serious allergic reaction requiring emergency treatment.
Common
May affect up to 1 in 10 patients
- Allergic reactions and infusion-related reactions (may develop rapidly during infusion; symptoms include breathing difficulties, rapid pulse, low blood pressure, skin rash)
- Nasal congestion (stuffy nose)
- Sore throat (nasopharyngitis)
- Fatigue (pronounced tiredness)
- Respiratory symptoms (runny nose, throat irritation, coughing, sneezing, shortness of breath)
Uncommon
May affect up to 1 in 100 patients
- Serious allergic reactions (anaphylaxis)
- Angioedema (swelling under the skin)
Infusion-related reactions are the most clinically relevant side effects of Vyepti. These reactions can range from mild respiratory symptoms (such as nasal congestion, runny nose, throat irritation, coughing, and sneezing) and tiredness to more serious allergic reactions including urticaria (hives), pruritis (itching), and, in rare cases, anaphylaxis. Most mild infusion-related symptoms resolve quickly on their own without specific treatment.
In the pivotal clinical trials (PROMISE-1 and PROMISE-2), the overall incidence of adverse events was similar between the Vyepti and placebo groups, indicating a generally favorable safety profile. The most commonly reported adverse events leading to discontinuation were hypersensitivity reactions, but these were infrequent. Long-term safety data from open-label extension studies have confirmed that Vyepti maintains a consistent safety profile over extended treatment periods of up to 2 years.
It is important to note that because Vyepti works by blocking CGRP, a molecule with vasodilatory properties, there has been theoretical concern about cardiovascular effects. However, no clinically significant cardiovascular safety signals have been identified in clinical trials or post-marketing surveillance. Blood pressure, heart rate, and cardiovascular event rates were similar between Vyepti-treated patients and those receiving placebo.
Reporting suspected side effects after a medicine has been authorized is important as it allows continuous monitoring of the medicine’s benefit-risk balance. Healthcare professionals and patients are encouraged to report any suspected adverse reactions to their national medicines regulatory authority (such as the FDA MedWatch program in the US, or the Yellow Card Scheme in the UK).
How Should You Store Vyepti?
Proper storage of Vyepti is essential to maintain the stability and efficacy of the medication. As a biological product (monoclonal antibody), eptinezumab is sensitive to temperature extremes, light exposure, and physical agitation. In most cases, Vyepti is stored and handled by healthcare professionals in hospital pharmacies or infusion centers, but the following storage guidelines apply:
- Refrigerated storage: Store unopened Vyepti vials in a refrigerator at 2–8°C (36–46°F). Keep the vials in the original outer carton to protect them from light.
- Do not freeze: Vyepti must not be frozen. Freezing can damage the protein structure of the monoclonal antibody and render the medication ineffective or potentially harmful.
- Do not shake: Vigorous shaking can cause protein aggregation and denaturation. Handle vials gently at all times.
- Room temperature storage: If Vyepti is removed from the refrigerator, it may be stored at room temperature (up to 25°C / 77°F) in its original packaging for a maximum of 7 days. After this period, any unused vials must be discarded. Once removed from refrigeration, do not return Vyepti to the refrigerator.
- After dilution: Once diluted for infusion, the prepared solution may be stored at room temperature (up to 25°C) or in a refrigerator at 2–8°C, but the infusion must be completed within 8 hours of preparation.
- Visual inspection: Before use, the solution should be visually inspected. Do not use Vyepti if the solution contains visible particles, appears cloudy, or is discolored (the normal appearance is clear to slightly opalescent, colorless to brownish yellow).
Keep Vyepti out of the sight and reach of children. Do not use the medication after the expiry date printed on the label and carton. The expiry date refers to the last day of the stated month. Unused medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures help to protect the environment.
What Does Vyepti Contain?
Understanding the composition of Vyepti is important for identifying potential allergens and ensuring that the medication is appropriate for each patient. Below is a detailed breakdown of the active and inactive ingredients:
Active Ingredient
Eptinezumab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody produced by recombinant DNA technology. It selectively binds to calcitonin gene-related peptide (CGRP) with high affinity, preventing CGRP from activating its receptor and thereby blocking the downstream signaling cascade involved in migraine pathophysiology. Two vial strengths are available:
- 100 mg vial: Contains 100 mg of eptinezumab per 1 mL of concentrate
- 300 mg vial: Contains 300 mg of eptinezumab per 3 mL of concentrate
Inactive Ingredients (Excipients)
| Excipient | Function | Important Notes |
|---|---|---|
| Sorbitol (E420) | Stabilizer / tonicity agent | Source of fructose; contraindicated in hereditary fructose intolerance |
| L-Histidine | Buffer (pH stabilization) | Amino acid naturally occurring in the body |
| L-Histidine hydrochloride monohydrate | Buffer (pH stabilization) | Salt form of L-histidine for precise pH control |
| Polysorbate 80 | Surfactant / stabilizer | May cause allergic reactions in sensitive individuals (0.15 mg/mL) |
| Water for injections | Solvent | Purified water meeting pharmacopeial standards |
Appearance and Packaging
Vyepti concentrate for solution for infusion is a clear to slightly opalescent, colorless to brownish yellow liquid. Each single-use vial contains the concentrate in a clear glass vial sealed with a rubber stopper, aluminum seal, and flip-off cap. The 100 mg strength is available in pack sizes of 1 and 3 single-use vials, while the 300 mg strength is available in packs containing 1 single-use vial. Not all pack sizes may be marketed in every country.
Frequently Asked Questions About Vyepti
Vyepti (eptinezumab) is used for the preventive treatment of migraine in adults who experience at least 4 migraine days per month. It works by targeting and neutralizing calcitonin gene-related peptide (CGRP), a key molecule involved in migraine pathophysiology. Vyepti is the only CGRP inhibitor given as an intravenous infusion, administered once every 12 weeks in a clinical setting. It can reduce the number of migraine days, improve quality of life, and begin working as early as the day after the first infusion.
The key difference is the route of administration. While Ajovy (fremanezumab), Aimovig (erenumab), and Emgality (galcanezumab) are given as subcutaneous (under the skin) self-injections at home, Vyepti is the only CGRP inhibitor administered as an intravenous infusion by a healthcare professional. This IV route provides immediate peak blood levels and potentially faster onset of action, with patients reporting fewer migraines as early as the day after their first infusion. However, it requires visiting a clinical setting every 12 weeks for the infusion.
Vyepti can begin working as early as the day after the first infusion. Because it is given intravenously, eptinezumab reaches maximum blood levels immediately at the end of the 30-minute infusion, with no absorption delay. In clinical trials, patients experienced significant reductions in migraine days within the first week. This rapid onset is a distinctive advantage compared to subcutaneous CGRP inhibitors, which may take several days to a week to reach peak blood levels. The full preventive benefit typically develops over the first few weeks and is sustained throughout the 12-week treatment cycle.
No, Vyepti cannot be self-administered at home. It is an intravenous medication that must be prepared and administered by a healthcare professional in a clinical setting such as a hospital outpatient unit or infusion center. The concentrate must be diluted before administration, and the infusion is given over approximately 30 minutes through a vein. During and after the infusion, healthcare staff monitor you for signs of allergic reactions. While this means a clinic visit every 12 weeks, some patients prefer this approach as it eliminates the need for self-injection.
If you experience any signs of an allergic reaction during your Vyepti infusion, tell your doctor or nurse immediately. Symptoms to watch for include difficulty breathing, rapid or weak pulse, sudden drop in blood pressure causing dizziness, swelling of the lips or tongue, and severe itching or skin rash. The healthcare team monitoring your infusion is trained to recognize and treat allergic reactions promptly. In most cases, mild symptoms resolve quickly after appropriate treatment. Your doctor will evaluate whether future infusions are appropriate based on the severity of the reaction.
No clinically significant drug interactions have been identified with Vyepti. As a monoclonal antibody, eptinezumab is not metabolized by the liver’s cytochrome P450 enzyme system and does not interact with other drugs through traditional mechanisms. You can generally continue using acute migraine treatments such as triptans, NSAIDs, and other analgesics while receiving Vyepti. Preventive medications like beta-blockers, anticonvulsants, and antidepressants can also be used concurrently. However, always inform your doctor about all the medications you take.
References
- European Medicines Agency (EMA). VYEPTI (eptinezumab) Summary of Product Characteristics. Last updated 2025. Available at: ema.europa.eu/en/medicines/human/EPAR/vyepti
- U.S. Food and Drug Administration (FDA). VYEPTI (eptinezumab-jjmr) Prescribing Information. Revised 2024. Available at: accessdata.fda.gov
- Ashina M, Saper J, Cady R, et al. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40(3):241-254. doi:10.1177/0333102420905132
- Lipton RB, Goadsby PJ, Smith J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology. 2020;94(13):e1365-e1377. doi:10.1212/WNL.0000000000009169
- American Headache Society. Consensus Statement: The American Headache Society Consensus Statement – Update on Integrating New Migraine Treatments into Clinical Practice. Headache. 2023;63(1):1-18.
- European Headache Federation (EHF). EHF Guidelines on the Use of Monoclonal Antibodies Acting on the Calcitonin Gene-Related Peptide or Its Receptor for Migraine Prevention. J Headache Pain. 2024;25:29.
- Dodick DW, Lipton RB, Silberstein S, et al. Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial. Cephalalgia. 2019;39(9):1075-1085.
- World Health Organization (WHO). WHO Model List of Essential Medicines, 23rd List. Geneva: WHO; 2023.
Editorial Team
Medical Content
iMedic Medical Editorial Team – Specialists in Neurology and Clinical Pharmacology
Medical Review
iMedic Medical Review Board – Independent panel of medical experts
Evidence Framework
GRADE methodology – Level 1A evidence from systematic reviews and RCTs
Sources
EMA SmPC, FDA Label, AHS Guidelines, EHF Guidelines, peer-reviewed journals
All content on iMedic is written by medical professionals and reviewed by specialist physicians. We follow international guidelines from the WHO, EMA, FDA, and leading medical societies. Our content is updated regularly to reflect the latest evidence and clinical recommendations. We receive no commercial funding and have no conflicts of interest.